Figure 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
DM by KRAS and assigned treatment. Distant failure rates based on treatment and KRAS-variant status, with KRAS-variant patients being depicted by blue lines and nonvariant patients by red lines and dashed lines representing cetuximab-treated patients.
Fields of Study & Subjects
Head and Neck Cancer Studies
Esophageal Cancer Research and Treatment
Lung Cancer Treatments and Mutations
Publication details
- Publication date
- 31 March 2026
- Language
- EN